PRKD2 and thyroid tumor: These included fusions PRKD2-BRAF, TFG-MET (n = 2), and TG-FGFR1, and mutations TSHR p.M453T and p.D633Y and BRAF p.T599del, all previously reported in thyroid tumors with the exception of the novel PRKD2-BRAF fusion (Data Supplement).1,18-20 Future studies are underway to more clearly define the influence of these genetic alterations on altered signaling pathways and thyroid cell differentiation.